Detection of Alzheimer's disease using cortical diffusion tensor imaging

for the Alzheimers Disease Neuroimage Initiative

Research output: Contribution to journalArticlepeer-review


The aim of this research was to test a novel in-vivo brain MRI analysis method that could be used in clinical cohorts to investigate cortical architecture changes in patients with Alzheimer's Disease (AD). Three cohorts of patients with probable AD and healthy volunteers were used to assess the results of the method. The first group was used as the “Discovery” cohort, the second as the “Test” cohort and the last “ATN” (Amyloid, Tau, Neurodegeneration) cohort was used to test the method in an ADNI 3 cohort, comparing to amyloid and Tau PET. The method can detect altered quality of cortical grey matter in AD patients, providing an additional tool to assess AD, distinguishing between these and healthy controls with an accuracy range between good and excellent. These new measurements could be used within the “ATN” framework as an index of cortical microstructure quality and a marker of Neurodegeneration. Further development may aid diagnosis, patient selection, and quantification of the “Neurodegeneration” component in response to therapies in clinical trials.

Original languageEnglish
Pages (from-to)967-977
Number of pages11
JournalHuman Brain Mapping
Issue number4
Publication statusPublished - Mar 2021
Externally publishedYes


  • Alzheimer's Disease
  • cortical diffusion tensor imaging
  • cortical microstructure
  • diagnostic accuracy
  • minicolumn

ASJC Scopus subject areas

  • Anatomy
  • Radiological and Ultrasound Technology
  • Radiology Nuclear Medicine and imaging
  • Neurology
  • Clinical Neurology

Cite this